KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? Lorusso D, Fuca G. Ann Oncol 2024;35:925-927.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lorusso D, Fuca G. KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? Ann Oncol 2024;35:925-927.
PMID: 39461745